287 related articles for article (PubMed ID: 30939452)
1. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
2. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
Florio T; Barbieri F; Spaziante R; Zona G; Hofland LJ; van Koetsveld PM; Feelders RA; Stalla GK; Theodoropoulou M; Culler MD; Dong J; Taylor JE; Moreau JP; Saveanu A; Gunz G; Dufour H; Jaquet P
Endocr Relat Cancer; 2008 Jun; 15(2):583-96. PubMed ID: 18509006
[TBL] [Abstract][Full Text] [Related]
4. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
6. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
[TBL] [Abstract][Full Text] [Related]
7. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
Ludvigsen E; Stridsberg M; Taylor JE; Culler MD; Oberg K; Janson ET
Med Oncol; 2004; 21(3):285-95. PubMed ID: 15456957
[TBL] [Abstract][Full Text] [Related]
8. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
9. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
Ibáñez-Costa A; López-Sánchez LM; Gahete MD; Rivero-Cortés E; Vázquez-Borrego MC; Gálvez MA; de la Riva A; Venegas-Moreno E; Jiménez-Reina L; Moreno-Carazo A; Tinahones FJ; Maraver-Selfa S; Japón MA; García-Arnés JA; Soto-Moreno A; Webb SM; Kineman RD; Culler MD; Castaño JP; Luque RM
Sci Rep; 2017 Feb; 7():42002. PubMed ID: 28181484
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
Jaquet P; Gunz G; Saveanu A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Enjalbert A; Culler MD
Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
[TBL] [Abstract][Full Text] [Related]
12. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.
Peverelli E; Olgiati L; Locatelli M; Magni P; Fustini MF; Frank G; Mantovani G; Beck-Peccoz P; Spada A; Lania A
Cancer Lett; 2010 Feb; 288(2):170-6. PubMed ID: 19619936
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
[TBL] [Abstract][Full Text] [Related]
14. The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells.
Zitzmann K; Andersen S; Vlotides G; Spöttl G; Zhang S; Datta R; Culler M; Göke B; Auernhammer CJ
Neuroendocrinology; 2013; 98(2):128-36. PubMed ID: 23797089
[TBL] [Abstract][Full Text] [Related]
15. Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells.
Herrera-Martínez AD; Feelders RA; Van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Castaño JP; de Herder WW; Hofland LJ
Neuroendocrinology; 2020; 110(5):351-363. PubMed ID: 31319410
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
Cuny T; Graillon T; Defilles C; Datta R; Zhang S; Figarella-Branger D; Dufour H; Mougel G; Brue T; Landsman T; Halem HA; Culler MD; Barlier A; Saveanu A
Pituitary; 2021 Jun; 24(3):351-358. PubMed ID: 33433890
[TBL] [Abstract][Full Text] [Related]
17. A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells.
Vázquez-Borrego MC; L-López F; Gálvez-Moreno MA; Fuentes-Fayos AC; Venegas-Moreno E; Herrera-Martínez AD; Blanco-Acevedo C; Solivera J; Landsman T; Gahete MD; Soto-Moreno A; Culler MD; Castaño JP; Luque RM
Neuroendocrinology; 2020; 110(1-2):70-82. PubMed ID: 31272096
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
Saveanu A; Lavaque E; Gunz G; Barlier A; Kim S; Taylor JE; Culler MD; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
[TBL] [Abstract][Full Text] [Related]
19. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]